Viracta Historical Income Statement

VIRX Stock

USD 0.15 0.01 7.14%

Historical analysis of Viracta Therapeutics income statement accounts such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M, Selling General Administrative of 13.7 M or Total Revenue of 0.0 can show how well Viracta Therapeutics performed in making a profits. Evaluating Viracta Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Viracta Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Viracta Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viracta Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

About Viracta Income Statement Analysis

Viracta Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Viracta Therapeutics shareholders. The income statement also shows Viracta investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Viracta Therapeutics Income Statement Chart

At this time, Viracta Therapeutics' Interest Expense is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 696.7 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 324.1 K in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Selling And Marketing Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Viracta Therapeutics. It is also known as Viracta Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Viracta Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.At this time, Viracta Therapeutics' Interest Expense is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 696.7 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 324.1 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	491K	577K	3.7M	3.9M
Depreciation And Amortization	178K	210K	492K	324.1K

Interest Expense Depreciation And Amortization

Viracta Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Income	Selling And Marketing Expenses	Net Interest Income	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation	Non Operating Income Net Other	Non Recurring
Depreciation And Amortization		0.01	-0.1	0.7	0.68	0.3	-0.03	0.0	0.6	0.01	0.3	0.02	0.04	0.02	-0.03	0.24	-0.07	0.12	-0.05	0.19	0.19	0.08	-0.15
Interest Expense	0.01		0.23	-0.11	-0.13	0.32	-0.48	-0.1	0.32	-0.1	0.32	-0.14	0.21	0.04	-0.21	0.83	-0.19	0.4	-0.03	0.57	0.54	0.46	-0.76
Selling General Administrative	-0.1	0.23		-0.22	-0.23	0.7	-0.2	-0.47	0.34	-0.47	0.7	-0.43	-0.1	-0.28	0.11	0.28	-0.24	0.44	-0.29	0.38	0.4	0.03	-0.11
Total Revenue	0.7	-0.11	-0.22		1.0	0.34	-0.07	0.28	0.61	0.29	0.34	0.3	0.19	0.25	-0.19	0.09	0.52	-0.27	0.35	-0.39	-0.4	0.05	0.27
Gross Profit	0.68	-0.13	-0.23	1.0		0.32	-0.06	0.29	0.59	0.3	0.32	0.32	0.19	0.26	-0.19	0.07	0.54	-0.29	0.37	-0.42	-0.43	0.04	0.3
Other Operating Expenses	0.3	0.32	0.7	0.34	0.32		-0.5	-0.06	0.81	-0.06	1.0	-0.03	0.29	0.12	-0.28	0.49	0.1	0.45	0.12	0.31	0.3	0.34	0.0
Operating Income	-0.03	-0.48	-0.2	-0.07	-0.06	-0.5		-0.61	-0.17	-0.61	-0.5	-0.61	-0.92	-0.79	0.91	-0.67	-0.17	-0.64	-0.68	-0.12	-0.1	-0.96	0.33
Ebit	0.0	-0.1	-0.47	0.28	0.29	-0.06	-0.61		-0.23	1.0	-0.06	0.99	0.87	0.96	-0.88	0.1	0.52	0.04	0.93	-0.43	-0.47	0.7	0.16
Research Development	0.6	0.32	0.34	0.61	0.59	0.81	-0.17	-0.23		-0.22	0.81	-0.2	0.0	-0.11	0.01	0.44	0.07	0.17	-0.08	0.31	0.3	0.06	-0.01
Ebitda	0.01	-0.1	-0.47	0.29	0.3	-0.06	-0.61	1.0	-0.22		-0.06	0.99	0.87	0.96	-0.88	0.11	0.52	0.05	0.93	-0.43	-0.47	0.7	0.15
Total Operating Expenses	0.3	0.32	0.7	0.34	0.32	1.0	-0.5	-0.06	0.81	-0.06		-0.03	0.29	0.12	-0.28	0.49	0.1	0.45	0.12	0.31	0.3	0.34	0.0
Income Before Tax	0.02	-0.14	-0.43	0.3	0.32	-0.03	-0.61	0.99	-0.2	0.99	-0.03		0.88	0.97	-0.88	0.1	0.52	0.05	0.94	-0.45	-0.49	0.7	0.19
Total Other Income Expense Net	0.04	0.21	-0.1	0.19	0.19	0.29	-0.92	0.87	0.0	0.87	0.29	0.88		0.97	-1.0	0.45	0.35	0.43	0.88	-0.15	-0.18	0.94	-0.11
Net Income	0.02	0.04	-0.28	0.25	0.26	0.12	-0.79	0.96	-0.11	0.96	0.12	0.97	0.97		-0.97	0.29	0.45	0.24	0.94	-0.31	-0.35	0.84	0.04
Income Tax Expense	-0.03	-0.21	0.11	-0.19	-0.19	-0.28	0.91	-0.88	0.01	-0.88	-0.28	-0.88	-1.0	-0.97		-0.46	-0.36	-0.41	-0.89	0.16	0.19	-0.93	0.11
Interest Income	0.24	0.83	0.28	0.09	0.07	0.49	-0.67	0.1	0.44	0.11	0.49	0.1	0.45	0.29	-0.46		-0.07	0.53	0.17	0.52	0.5	0.67	-0.75
Selling And Marketing Expenses	-0.07	-0.19	-0.24	0.52	0.54	0.1	-0.17	0.52	0.07	0.52	0.1	0.52	0.35	0.45	-0.36	-0.07		-0.52	0.68	-0.74	-0.77	0.09	0.53
Net Interest Income	0.12	0.4	0.44	-0.27	-0.29	0.45	-0.64	0.04	0.17	0.05	0.45	0.05	0.43	0.24	-0.41	0.53	-0.52		-0.04	0.64	0.66	0.65	-0.54
Net Income From Continuing Ops	-0.05	-0.03	-0.29	0.35	0.37	0.12	-0.68	0.93	-0.08	0.93	0.12	0.94	0.88	0.94	-0.89	0.17	0.68	-0.04		-0.54	-0.57	0.68	0.24
Cost Of Revenue	0.19	0.57	0.38	-0.39	-0.42	0.31	-0.12	-0.43	0.31	-0.43	0.31	-0.45	-0.15	-0.31	0.16	0.52	-0.74	0.64	-0.54		1.0	0.17	-0.67
Reconciled Depreciation	0.19	0.54	0.4	-0.4	-0.43	0.3	-0.1	-0.47	0.3	-0.47	0.3	-0.49	-0.18	-0.35	0.19	0.5	-0.77	0.66	-0.57	1.0		0.14	-0.66
Non Operating Income Net Other	0.08	0.46	0.03	0.05	0.04	0.34	-0.96	0.7	0.06	0.7	0.34	0.7	0.94	0.84	-0.93	0.67	0.09	0.65	0.68	0.17	0.14		-0.42
Non Recurring	-0.15	-0.76	-0.11	0.27	0.3	0.0	0.33	0.16	-0.01	0.15	0.0	0.19	-0.11	0.04	0.11	-0.75	0.53	-0.54	0.24	-0.67	-0.66	-0.42

Click cells to compare fundamentals

Viracta Therapeutics Account Relationship Matchups

Viracta Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.1K	32K	178K	210K	492K	324.1K
Interest Expense	514K	216K	491K	577K	3.7M	3.9M
Selling General Administrative	3.2M	5.3M	15.4M	24.3M	17.3M	13.7M
Gross Profit	2.1M	88K	(178K)	(210K)	(492K)	(467.4K)
Other Operating Expenses	25.4M	18.8M	25.8M	50.6M	50.7M	29.3M
Operating Income	(23.3M)	(18.8M)	62.5M	(50.6M)	(50.7M)	(53.2M)
Ebit	(12.1M)	(18.8M)	(114.3M)	(50.6M)	(47.4M)	(49.7M)
Research Development	15.4M	13.5M	23.9M	26.3M	33.4M	19.6M
Ebitda	(12.1M)	(18.8M)	(114.1M)	(50.4M)	(46.9M)	(49.2M)
Total Operating Expenses	25.4M	18.8M	25.8M	50.6M	50.7M	29.3M
Income Before Tax	(23.3M)	(19.0M)	(114.8M)	(49.2M)	(51.1M)	(53.6M)
Total Other Income Expense Net	(42K)	(202K)	(75.5M)	1.4M	(365K)	(383.3K)
Net Income	(23.3M)	(19.2M)	(203.1M)	(49.8M)	(51.1M)	(53.6M)
Income Tax Expense	514K	182K	88.3M	577K	663.6K	696.7K
Interest Income	514K	302K	38K	1.2M	3.2M	3.4M
Net Income Applicable To Common Shares	(13.6M)	(19.0M)	(114.8M)	(49.2M)	(44.3M)	(46.5M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viracta Historical Income Statement

About Viracta Income Statement Analysis

Viracta Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Viracta Therapeutics income statement Correlations

Viracta Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viracta Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Viracta Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Reconciled Depreciation	+ 1.0	Cost Of Revenue
Income Before Tax	+ 0.99	Ebit
Income Before Tax	+ 0.99	Ebitda

Income Tax Expense	- 1.0	Total Other Income Expense Net
Income Tax Expense	- 0.97	Net Income
Non Operating Income Net Other	- 0.96	Operating Income
Non Operating Income Net Other	- 0.93	Income Tax Expense
Total Other Income Expense Net	- 0.92	Operating Income
Net Income From Continuing Ops	- 0.89	Income Tax Expense